The membership of the NHLBI Gene Therapy Group is comprised of the Group Leader, Project Officers from multiple divisions of the NHLBI, and members of the Grants Management Office and Office of Acquisitions. The GTRP Program was initiated under the leadership of the late Dr. Sonia Skarlatos. Dr. Cheryl L. McDonald, of the NHLBI's Division of Cardiovascular Sciences, was subsequently appointed Gene Therapy Group Leader and has been serving in that role since 2013. Ancillary members may be appointed by the group leader.

The Gene Therapy Group is charged with oversight and overall management of all components of the GTRP including development and maintenance of program infrastructure. This includes:

  • Developing and implementing Bylaws and Policies of the GTRP
  • Creating committees, review boards, and working groups as deemed appropriate including delegation of responsibility and authority
  • Determining (as the sole review group) disposition of Request for Service Applications for Preclinical Vector Production and Regulatory Support Services
  • Determining final disposition of Request for Service Applications for Pharmacology/Toxicology Testing and Clinical Trial Funding Assistance

Business of the Gene Therapy Group is conducted primarily through face-to-face meetings and teleconferences.

Gene Therapy Group Roster